You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Medical Care

Global Focal Segmental Glomerulosclerosis (FSGS) Industry Research Report, Growth Trends and Competitive Analysis 2021-2027

Focal Segmental Glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults.
The global Focal Segmental Glomerulosclerosis (FSGS) market size is projected to reach US$ 9733.1 million by 2027, from US$ 7517.1 million in 2020, at a CAGR of 4.4% during 2021-2027.
In terms of production side, this report researches the Focal Segmental Glomerulosclerosis (FSGS) production capacity, value, ex-factory price, growth rate, market share by manufacturers, regions (or countries) and by Type.
In terms of consumption side, this report focuses on the consumption of Focal Segmental Glomerulosclerosis (FSGS) by regions (countries) and by Application.
The global Focal Segmental Glomerulosclerosis (FSGS) market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Focal Segmental Glomerulosclerosis (FSGS) market. These figures have been provided in terms of both revenue and volume for the period 2016-2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise Focal Segmental Glomerulosclerosis (FSGS) markets such as North America, Europe, China and Japan, etc. Key regions covered in the report are U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E
For the period 2016-2027, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Focal Segmental Glomerulosclerosis (FSGS) market. For the period 2016-2021, it provides sales (consumption) analysis and forecast of different regional markets by each application as well as type segment in terms of volume.
Manufacturers
The report includes comprehensive company profiling of leading and emerging companies competing in the global Focal Segmental Glomerulosclerosis (FSGS) market. It provides a detailed list of players operating at a global level. The players have been listed according to the type of products they offer in the global Focal Segmental Glomerulosclerosis (FSGS) market and other factors. As part of the company profiling, the analysts authoring the report has provided the market entry year of each player considered for the research study. The report also offers extensive price, volume sales, and revenue analysis by the manufacturer at the global level for the period 2016-2021.
By Type and Application Segments
The report includes a detailed analysis of leading and type and application segments of the global Focal Segmental Glomerulosclerosis (FSGS) market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue sales analysis and forecast of the global Focal Segmental Glomerulosclerosis (FSGS) market by each type segment for the period 2016-2027. It also offers volume sales (consumption) analysis and forecast of the global Focal Segmental Glomerulosclerosis (FSGS) market by each type segment for the same period. Also, it provides volume sales (consumption) analysis and forecast of the global Focal Segmental Glomerulosclerosis (FSGS) market by each application segment for the same period.
This report includes the following manufacturers:
Variant Pharmaceuticals
ChemoCentryx
Retrophin
Novartis
Pfizer
AstraZeneca
Sanofi
GlaxoSmithKline
Teva Pharmaceutical
Market Segment by Type
Diagnosis (Kidney Biopsy and Creatine Test)
Treatment (Drug Therapy, Dialysis, and Kidney Transplant)
Market Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Research Methodology
To compile the detailed study of the global Focal Segmental Glomerulosclerosis (FSGS) market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the Focal Segmental Glomerulosclerosis (FSGS) market. LBI Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the Focal Segmental Glomerulosclerosis (FSGS) market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.
1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Type
1.2.2 Diagnosis (Kidney Biopsy and Creatine Test)
1.2.3 Treatment (Drug Therapy, Dialysis, and Kidney Transplant)
1.3 Market Segment by Application
1.3.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Application (2016 VS 2021 VS 2027)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered

2 Market Perspective
2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size (2016-2027)
2.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue (2016-2027)
2.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Sales (2016-2027)
2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size across Key Geographies Worldwide: 2016 VS 2021 VS 2027
2.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales by Regions (2016-2021)
2.2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue by Regions (2016-2021)
2.3 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast by Region
2.3.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Region (2022-2027)
2.3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Region (2022-2027)
2.4 Global Top Focal Segmental Glomerulosclerosis (FSGS) Regions (Countries) Ranking by Market Size
2.5 Focal Segmental Glomerulosclerosis (FSGS) Industry Trends
2.5.1 Focal Segmental Glomerulosclerosis (FSGS) Market Trends
2.5.2 Focal Segmental Glomerulosclerosis (FSGS) Market Drivers
2.5.3 Focal Segmental Glomerulosclerosis (FSGS) Market Challenges
2.5.4 Focal Segmental Glomerulosclerosis (FSGS) Market Restraints

3 Competitive Landscape by Manufacturers
3.1 Global Top Focal Segmental Glomerulosclerosis (FSGS) Manufacturers by Sales (2016-2021)
3.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales by Manufacturers (2016-2021)
3.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Manufacturers (2016-2021)
3.1.3 Global 5 and 10 Largest Manufacturers by Focal Segmental Glomerulosclerosis (FSGS) Sales in 2020
3.2 Global Top Manufacturers Focal Segmental Glomerulosclerosis (FSGS) by Revenue
3.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue by Manufacturers (2016-2021)
3.2.2 Top Focal Segmental Glomerulosclerosis (FSGS) Manufacturers Covered: Ranking by Revenue
3.2.3 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Focal Segmental Glomerulosclerosis (FSGS) Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Focal Segmental Glomerulosclerosis (FSGS) as of 2020)
3.4 Global Focal Segmental Glomerulosclerosis (FSGS) Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Focal Segmental Glomerulosclerosis (FSGS) Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Focal Segmental Glomerulosclerosis (FSGS) Market
3.7 Key Manufacturers Focal Segmental Glomerulosclerosis (FSGS) Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size by Type
4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Historic Market Review by Type (2016-2021)
4.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Type (2016-2021)
4.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Type (2016-2021)
4.1.3 Focal Segmental Glomerulosclerosis (FSGS) Price by Type (2016-2021)
4.2 Global Focal Segmental Glomerulosclerosis (FSGS) Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Type (2022-2027)
4.2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Type (2022-2027)
4.2.3 Focal Segmental Glomerulosclerosis (FSGS) Price Forecast by Type (2022-2027)

5 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size by Application
5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Historic Market Review by Application (2016-2021)
5.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Application (2016-2021)
5.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Application (2016-2021)
5.1.3 Focal Segmental Glomerulosclerosis (FSGS) Price by Application (2016-2021)
5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Application (2022-2027)
5.2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Application (2022-2027)
5.2.3 Focal Segmental Glomerulosclerosis (FSGS) Price Forecast by Application (2022-2027)

6 North America
6.1 North America Focal Segmental Glomerulosclerosis (FSGS) Sales Breakdown by Company
6.1.1 North America Focal Segmental Glomerulosclerosis (FSGS) Sales by Company (2016-2027)
6.1.2 North America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Company (2016-2027)
6.2 North America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Type (2016-2027)
6.2.1 North America Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2016-2027)
6.2.2 North America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Type (2016-2027)
6.3 North America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Application (2016-2027)
6.3.1 North America Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2016-2027)
6.3.2 North America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Application (2016-2027)
6.4 North America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country
6.4.1 North America Focal Segmental Glomerulosclerosis (FSGS) Sales by Country (2016-2027)
6.4.2 North America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country (2016-2027)
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Sales Breakdown by Company
7.1.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Sales by Company (2016-2027)
7.1.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue by Company (2016-2027)
7.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size by Type (2016-2027)
7.2.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2016-2027)
7.2.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue by Type (2016-2027)
7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size by Application (2016-2027)
7.3.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2016-2027)
7.3.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue by Application (2016-2027)
7.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country
7.4.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Sales by Country (2016-2027)
7.4.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country (2016-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales Breakdown by Company
8.1.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales by Company (2016-2027)
8.1.2 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue by Company (2016-2027)
8.2 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size by Type (2016-2027)
8.2.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2016-2027)
8.2.2 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue by Type (2016-2027)
8.3 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size by Application (2016-2027)
8.3.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2016-2027)
8.3.2 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue by Application (2016-2027)
8.4 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size by Regions
8.4.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales by Regions
8.4.2 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales Breakdown by Company
9.1.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales by Company (2016-2027)
9.1.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Company (2016-2027)
9.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Type (2016-2027)
9.2.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2016-2027)
9.2.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Type (2016-2027)
9.3 Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Application (2016-2027)
9.3.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2016-2027)
9.3.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Application (2016-2027)
9.4 Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country
9.4.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales by Country (2016-2027)
9.4.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country (2016-2027)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales Breakdown by Company
10.1.1 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales by Company (2016-2027)
10.1.2 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue by Company (2016-2027)
10.2 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size by Type (2016-2027)
10.2.1 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2016-2027)
10.2.2 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue by Type (2016-2027)
10.3 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size by Application (2016-2027)
10.3.1 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2016-2027)
10.3.2 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue by Application (2016-2027)
10.4 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country
10.4.1 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales by Country (2016-2027)
10.4.2 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country (2016-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 U.A.E

11 Company Profiles
11.1 Variant Pharmaceuticals
11.1.1 Variant Pharmaceuticals Corporation Information
11.1.2 Variant Pharmaceuticals Overview
11.1.3 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.1.4 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Products and Services
11.1.5 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) SWOT Analysis
11.1.6 Variant Pharmaceuticals Recent Developments
11.2 ChemoCentryx
11.2.1 ChemoCentryx Corporation Information
11.2.2 ChemoCentryx Overview
11.2.3 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.2.4 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Products and Services
11.2.5 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) SWOT Analysis
11.2.6 ChemoCentryx Recent Developments
11.3 Retrophin
11.3.1 Retrophin Corporation Information
11.3.2 Retrophin Overview
11.3.3 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.3.4 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Products and Services
11.3.5 Retrophin Focal Segmental Glomerulosclerosis (FSGS) SWOT Analysis
11.3.6 Retrophin Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Overview
11.4.3 Novartis Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.4.4 Novartis Focal Segmental Glomerulosclerosis (FSGS) Products and Services
11.4.5 Novartis Focal Segmental Glomerulosclerosis (FSGS) SWOT Analysis
11.4.6 Novartis Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Overview
11.5.3 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.5.4 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Products and Services
11.5.5 Pfizer Focal Segmental Glomerulosclerosis (FSGS) SWOT Analysis
11.5.6 Pfizer Recent Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Corporation Information
11.6.2 AstraZeneca Overview
11.6.3 AstraZeneca Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.6.4 AstraZeneca Focal Segmental Glomerulosclerosis (FSGS) Products and Services
11.6.5 AstraZeneca Focal Segmental Glomerulosclerosis (FSGS) SWOT Analysis
11.6.6 AstraZeneca Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Overview
11.7.3 Sanofi Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.7.4 Sanofi Focal Segmental Glomerulosclerosis (FSGS) Products and Services
11.7.5 Sanofi Focal Segmental Glomerulosclerosis (FSGS) SWOT Analysis
11.7.6 Sanofi Recent Developments
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Corporation Information
11.8.2 GlaxoSmithKline Overview
11.8.3 GlaxoSmithKline Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.8.4 GlaxoSmithKline Focal Segmental Glomerulosclerosis (FSGS) Products and Services
11.8.5 GlaxoSmithKline Focal Segmental Glomerulosclerosis (FSGS) SWOT Analysis
11.8.6 GlaxoSmithKline Recent Developments
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Corporation Information
11.9.2 Teva Pharmaceutical Overview
11.9.3 Teva Pharmaceutical Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.9.4 Teva Pharmaceutical Focal Segmental Glomerulosclerosis (FSGS) Products and Services
11.9.5 Teva Pharmaceutical Focal Segmental Glomerulosclerosis (FSGS) SWOT Analysis
11.9.6 Teva Pharmaceutical Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 Focal Segmental Glomerulosclerosis (FSGS) Value Chain Analysis
12.2 Focal Segmental Glomerulosclerosis (FSGS) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Focal Segmental Glomerulosclerosis (FSGS) Production Mode & Process
12.4 Focal Segmental Glomerulosclerosis (FSGS) Sales and Marketing
12.4.1 Focal Segmental Glomerulosclerosis (FSGS) Sales Channels
12.4.2 Focal Segmental Glomerulosclerosis (FSGS) Distributors
12.5 Focal Segmental Glomerulosclerosis (FSGS) Customers
13 Research Findings and Conclusion

14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
  • FORMAT: PDF
  • PUBLISHED DATE: Mar, 2021
  • NO OF PAGES: 104